At 90 days, participants randomized to the Felix NeuroAI transcutaneous peripheral nerve stimulation (TPNS) system showed ...

Colleges and teaching hospitals are the cornerstones of the city’s economy — and identity. But federal funding cuts to higher ...

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...

The pharmaceutical company says it will continue to operate its production facility near Research Triangle Park.

Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first ... families,” said Sylvia Boesch of Medical University Innsbruck in Austria, who was principal ...

But with new technology based on branched silencing RNA licensed from the University of Massachusetts ... The partnership with Biogen will develop RNAi therapeutics for multiple targets, including ...